Skip to content

News

USPSTF Releases Draft Statement on Risk Assessment for BRCA...

USPSTF Releases Draft Statement on Risk Assessment for BRCA-Related Cancer

On Tuesday, April 2, the U.S. Preventive Services Task Force (USPSTF) released its draft recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. The USPSTF recommends that primary care providers screen women who have family members with breast or ovarian cancer with one of several screening tools designed to identify a … Continued

Depression and Anxiety Drug May Ease Neuropathy from Chemo

Depression and Anxiety Drug May Ease Neuropathy from Chemo

Research published today in the Journal of the American Medical Association showed that the depression and anxiety drug duloxetine effectively treated painful chemotherapy-induced peripheral neuropathy. Chemotherapy-induced peripheral neuropathy occurs in roughly 20% to 40% of patients treated with chemotherapy agents such as taxanes, platinums, and vinca alkaloids.  The condition can persist for years following treatment … Continued

Report from the Society of Gynecologic Oncology 2013 Annual...

Report from the Society of Gynecologic Oncology 2013 Annual Meeting

At this year’s Society of Gynecologic Oncology (SGO) Annual Meeting, numerous presentations and posters explored issues related to ovarian cancer, some of which are summarized below. This year’s SGO Annual Meeting theme, “Embrace the Past, Revolutionize the Future,” was especially fitting given the changing landscape of ovarian cancer treatment. As the Cancer Genome Atlas reveals … Continued

Partner Member Profile: Ovarian Cancer Alliance of San Diego

Partner Member Profile: Ovarian Cancer Alliance of San Diego

Ovarian cancer survivor Peg Ford first heard about our Survivors Teaching Students: Saving Women’s Lives® (STS) program while searching for a support group in her hometown of San Diego, California. At the time, there was no local group doing work on ovarian cancer. Peg was inspired by what she learned about STS and said, “That’s … Continued

New Genetic Markers for Ovarian Cancer Discovered

New Genetic Markers for Ovarian Cancer Discovered

A collaboration of more than 130 institutions analyzing data from more than 200,000 people found two new genetic markers increasing a woman’s risk of developing ovarian cancer. New risk-modifying loci were identified for breast (n = 1) and ovarian (n = 2) cancers in BRCA1 mutation carriers and for breast cancer (n = 1) in … Continued

OCRF Research Identifies Genetic Variations Increasing Ovar...

OCRF Research Identifies Genetic Variations Increasing Ovarian Cancer Risk

As part of a huge international effort involving more than 100 institutions and genetic tests on 200,000 people, researchers have discovered dozens of signposts in DNA that can help reveal further a person’s risk for breast, ovarian or prostate cancer.  The OCRF-funded Ovarian Cancer Association Consortium contributed to the ovarian cancer-related findings: five new genetic … Continued

The New York Times Publishes OCRF's Letter to the Edit...

The New York Times Publishes OCRF's Letter to the Editor 3/12/13

A frequent New York Times commenter on important ovarian cancer issues, OCRF wrote a Letter to the Editor in response to the NYT editorial, “Inadequate Treatment of Ovarian Cancer,” which was published in print and online on March 21, 2013. We are grateful for the opportunity to reach such a large audience regarding the importance of seeking … Continued

Night Shift Work May Increase Risk of Ovarian Cancer

Night Shift Work May Increase Risk of Ovarian Cancer

A study by researchers from the Fred HutchinsonCancer Research Center in Seattle found that women working the night shift may be at higher risk for ovarian cancer. The study of 3,322 women was published in the Journal of Occupational and Environmental Medicine.  NIght shift work was associated with a 24 percent higher risk of advanced ovarian … Continued

Abagovomab As Maintenance Therapy in Patients With Epitheli...

Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer

In research published online on March 11, 2013 in the Journal of Clinical Oncology, researchers report on the results of a phase III, double-blind, placebo-controlled multicenter study that evaluated whether using abagovomab as maintenance therapy prolongs recurrence-free survival and overall survival in patients with ovarian cancer in patients in their first remission. This clinical trial was … Continued

News from the SGO Annual Meeting

News from the SGO Annual Meeting

From March 9-12, 2013 top women’s cancer doctors from all over the world met in Los Angeles for the Society of Gynecologic Oncology‘s Annual Meeting on Women’s Cancer.  Lots of exciting research was presented at the meeting, representing the latest in the care and treatment of women with ovarian and other gynecologic cancers.  Highlights from research … Continued

IP Chemo Shows Survival Benefit

IP Chemo Shows Survival Benefit

Two studies recently released show a survival benefit for intraperitoneal IP chemotherapy Women with the BRCA1 mutation given IP chemotherapy survived three years longer than those given IV chemotherapy. Read an article about the study here. A study presented at the SGO Annual Meeting showed an improvement in median survival of 10 months.

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.